{"schema_version":"secwatch.filing_event.v1","accession":"0001842952-24-000022","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.700082+00:00","generated_at":"2026-06-04T04:55:31.726510+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Context Therapeutics submits IND for CTIM-76 Phase 1 trial in CLDN6-positive cancers","bullets":["IND filed March 28, 2024 with FDA for CTIM-76, a CLDN6 x CD3 bispecific antibody.","Phase 1 dose escalation/expansion trial planned in CLDN6-positive gynecologic and testicular cancers.","CEO Martin Lehr calls IND submission a significant milestone for the company.","Company set aggressive 2021 timeline and prioritized CTIM-76 as potentially best-in-class therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001842952-24-000022","json":"https://secwatch.observer/filing/0001842952-24-000022.json","markdown":"https://secwatch.observer/filing/0001842952-24-000022.md","text":"https://secwatch.observer/filing/0001842952-24-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000184295224000022/0001842952-24-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000184295224000022/cntx-20240401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:55:31.726510+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}